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Massimo Filippi, MD, PhD, Jordi Rio, MD, Jacqueline Palace, MD, Maria A. Rocca, MD, PhD, Olga Ciccarelli, MD,
PhD, Frederik Barkhof, MD, PhD, Jaume Sastre-Garriga, MD, PhD, Hugo Vrenken, PhD,
Jette L. Frederiksen, MD, Tarek A. Yousry, MD, Christian Enzinger, MD, Alex Rovira, MD, Ludwig Kappos, MD,







Over the last few decades, the improved diagnostic criteria, the wide use of MRI, and the
growing availability of effective pharmacologic treatments have led to substantial advances in
the management of multiple sclerosis (MS). The importance of early diagnosis and treatment is
now well-established, but there is still no consensus on how to define and monitor response to
MS treatments. In particular, the clinical relevance of the detection of minimal MRI activity is
controversial and recommendations on how to define and monitor treatment response are
warranted. An expert panel of the Magnetic Resonance Imaging in MS Study Group analyzed
and discussed published studies on treatment response in MS. The evolving concept of no
evidence of disease activity and its effect on predicting long-term prognosis was examined,
including the option of defining a more realistic target for daily clinical practice: minimal
evidence of disease activity. Advantages and disadvantages associated with the use of MRI
activity alone and quantitative scoring systems combining on-treatment clinical relapses and
MRI active lesions to detect treatment response in the real-world setting were also discussed.
While most published studies on this topic involved patients treated with interferon-β, special
attention was given to more recent studies providing evidence based on treatment with other
and more efficacious oral and injectable drugs. Finally, the panel identified future directions to
pursue in this research field.
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With the progress of therapeutics, we have learned that the
natural history of multiple sclerosis (MS) can be modified by
treatment and that beginning treatment early in the disease
course results in better medium-term clinical outcomes than
delaying treatment. Given the rapidly expanding range of
treatments available for relapsing-remitting MS (RRMS), it
would be of crucial importance to predict the individual
patient’s response in order to make optimal therapeutic
decisions. However, we are still far from precision medicine in
the MS field, since at present no predictive and easily re-
producible biomarkers have been found beyond clinical as-
sessment, conventional MRI measures, and neutralizing
antibodies to some drugs. Furthermore, we have to consider
that (1) there is no shared definition for treatment response
in MS; (2) there is still much debate about which markers
(clinical relapses, confirmed disability worsening, MRI activity,
or a combination of all) should be used to predict treatment
response upon implementation of a specific disease-modifying
drug; (3) the vast majority of studies on this topic were con-
ducted on interferon-β (IFN-β)–treated patients, thus raising
the question of whether we can use the same tools to predict
response across different treatments.
Despite these difficulties, the early prediction of treatment
response is a central goal in the field of MS research. In this
review, recommendations on how MRI should be used to
define and monitor treatment response are given and
knowledge gaps to be filled in this research field are discussed
on the basis of the published evidence and expert opinion.
Methodologic issues
An international workshop was held in Rome, Italy, in Sep-
tember 2015 under the auspices of MAGNIMS (Magnetic
Resonance Imaging in MS), an intellectually independent
network of European clinical research groups that have an
interest in the use of MRI to study patients with MS (mag-
nims.eu). The panel convened to the workshop was com-
posed of experts in the diagnosis and management of MS, and
included neurologists, neuroradiologists, statisticians, and
physicists from MAGNIMS-affiliated institutions.
The panel met to present and discuss data from published
research studies and to consider the recommendations con-
tained in previous articles related to the management of
patients with MS under pharmacologic treatment. After the
meeting, the panel continued to discuss the latest evidence in
this field, in order to set out specific and fully updated rec-
ommendations, and the relevant publications on the topic
were reviewed (until December 2017). The first draft of the
manuscript was written by the principal author and was based
on contributions from each panelist. The draft was then cir-
culated to all members, who iteratively modified the docu-
ment until a final consensus was reached.
Data availability
E-references are available from MAGNIMS (magnims.eu/?
protected-download=16119).
Definition of treatment response
The concepts of response and nonresponse, as well as the
time frame during which this is assessed, are widely mixed in
the literature. Nonresponse to a treatment is defined on the
basis of 3 outcomes or their combination: worsening of dis-
ability, incidence of relapses, and presence of active MRI
lesions (defined as new/enlarged T2 lesions or gadolinium-
enhanced lesions).
In many studies based on a short/medium-term follow-up
period, the definition of a nonresponse has been based on a 1.0-
point increase in the Expanded Disability Status Scale (EDSS)
confirmed at 6 months,1 independently of the duration of
clinical follow-up (usually ranging from 1 to 6 years). In longer-
term studies (15–16 years), nonresponders were defined on
the basis of a net increase in the EDSS,2 the milestone of
reaching EDSS ≥6.0, and a transition to the secondary pro-
gressive (SP) phase.3 Other definitions of nonresponse pro-
posed in the literature encompass the combination of EDSS
worsening or relapses,1,4,5 an increased relapse rate as com-
pared to the pretreatment relapse frequency,6,7 the presence of
activeMRI lesions during treatment,8,9 and switching from one
drug to another.10,11
No evidence vs minimal evidence of
disease activity
With increasingly effective therapies, no evidence of disease
activity (NEDA) has gathered increasing consideration as
a treatment goal. NEDA is a composite score based on the
Glossary
BBB = blood–brain barrier; CMSWG = Canadian MS Working Group; EDSS = Expanded Disability Status Scale;
FREEDOMS = Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis; GA =
glatiramer acetate; HR = hazard ratio; IFN-β = interferon-β; MEDA = minimal evidence of disease activity; MS = multiple
sclerosis; NEDA = no evidence of disease activity; PRISMS = Prevention of Relapses and disability by Interferon beta-1a
Subcutaneously in Multiple Sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple
sclerosis; TOR = Treatment Optimization Recommendations.
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zero tolerance concept entailing the absence of relapses, no
confirmed EDSS worsening, and no active lesions on an-
nual brain MRI scans.12 This latter definition, also so-called
NEDA-3, is mainly driven by focal inflammatory activity
rather than neurodegenerative processes. Therefore, recently, it
has been proposed to also include brain atrophy (NEDA-4)
(figure 1) based on a meta-analysis13 demonstrating that both
focal T2 lesions and an annual brain volume loss >0.4% during
treatment explained 75% of the variance of disability worsening
over 2 on-treatment years, and that their combination is better
than either metric alone.14 CSF or serum biomarkers (neuro-
filament light chain as a specificmarker of neuroaxonal integrity
seems particularly promising) might also help in assessing the
persistence of subtle inflammation and insidious neurodegen-
erative process.15
Other metrics assessing cognitive status, neurophysiologic
features, retinal structure, patient-reported outcomes (in-
cluding quality of life), as well as spinal cord imaging, could
also be incorporated into the NEDA definition in the future to
provide a composite endpoint for better assessing treatment
efficacy in clinical trials. On the other hand, all the afore-
mentioned assessments are currently not applicable routinely
in daily clinical practice. As a consequence, NEDA-3 appears
to be the only goal we are able to assess in a real-world setting
at present, but we must take into account that the achievement
of a NEDA-3 status does not preclude cognitive deterioration,
neurodegeneration, or disease progression. Moreover, we must
also consider that NEDA-3 is MRI-biased, since MRI lesions
are more frequent than clinical attacks.
From a more practical point of view, the most important
question concerns the persistence of NEDA over time and its
accuracy for predicting long-term prognosis.16–18 Preliminary
data suggest that NEDA is difficult to sustain over the long term
with platform therapies (from 0% to less than 10% over a time
period of 7–10 years). Indeed, longer-term disease remission
(about 30%–40% over a time period of 5–7 years) has been
instead described with monoclonal antibodies or after autolo-
gous hematopoietic stem cell transplantation (67% at 5 years),
but with a greater burden in terms of surveillance and ad-
verse events (table 1).e1–e18 It must be stressed, however, that
comparisons of independent studies conducted on different
treatment populations should be interpreted with caution.
Since NEDA-3 might be considered a too stringent treat-
ment goal, tolerance of a minimal evidence of disease activity
(MEDA) may represent a more realistic goal to strive for,
without exposing patients at risk of long-term poor outcomes.
However, only a few studies explored the predictive value of
early NEDA and MEDA in identifying the IFN-β-treated
patients who will attain clinically meaningful disability out-
comes in the long-term period. In one study,18 MEDA was
defined as experiencing either 1 relapse with <3 new T2 lesions
or <2 gadolinium-enhancing lesions during the first year of
treatment. A minimal degree of activity did not seem predictive
of EDSS worsening over a 7-year follow-up. More recently,
Prosperini et al.19 provided real-world data showing that the
adopted definition of MEDA affected the long-term risk of
reaching the disability milestone of EDSS 6.0 in 1,195 patients
treated with IFN-β or glatiramer acetate (GA). A definition of
MEDA based upon <2 gadolinium-enhancing lesions and <3
new T2 lesions did not imply an increased risk, whereas the
occurrence of even a single relapse during the first treatment
year was associated with long-term poor outcome.
Indicators of treatment response
There is confusion in the literature on the properties of baseline
factors distinguishing prognostic markers from markers of re-
sponse to treatment. A prognostic factor is a baseline measure
that is associated with a subsequent outcome (such as death,
relapse, or disability progression). The definition of a prog-
nostic factor is independent from treatments and prognostic
markers assessment can be done with or without a control
group. A treatment effect modifier is a baseline factor that is
associated with a higher or lower treatment effect. An effect
Figure 1 Definition of the concept of no evidence of disease activity (NEDA)
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modifier can be defined only in relation to a specific treatment
and the assessment of a treatment effect modifier must be done
in presence of a control group, by an interaction analysis.
Demographic, clinical, and MRI markers at baseline that can
be considered treatment effect modifiers have been assessed
in a recent meta-analysis of subgroup analyses of randomized
trials performed in patients with RRMS, showing that a higher
treatment benefit is associated with baseline characteristics of
earlier (younger age and lower EDSS) andmore active disease
on MRI (higher gadolinium enhancement activity).20 Earlier
observational studies6,7,21 and more recent large studies from
the MSBase Study Group22,23 explored which demographic
and clinical characteristics, considered at treatment start, were
associated with prognosis over short-term follow-up periods.
Modifiers of treatment response comprised age, disease du-
ration, disease course, previous relapse activity, disability,
predominant relapse phenotype, and previous therapy, but
the magnitude and direction of these associations are highly
variable across different therapies and are affected by the
considered outcome (relapse, disability worsening, or re-
gression).23 Although these baseline indicators were often
described as predictors, they should be considered merely as
prognostic indicators since they were analyzed without
a control group of nontreated patients.20
A dynamic scenario is necessary to talk about surrogate
markers: variables that can be detected earlier after treatment
initiation than the final outcome and that mediate the effect of
the treatment on such an outcome. In other words, the
treatment effect on the surrogate marker should predict the
treatment effect on the final clinical outcome of interest.
According to different studies, the treatment effect on relapses
in the first treatment year predicted ;62% and ;80% of the
treatment effect on the 2-year disability worsening in IFN-β-
and natalizumab-treated patients, respectively.24,25 In analogy,
the treatment effect on new T2 lesions in the first treatment
year predicted;60% of the treatment effect on relapses26 and
;57% of the treatment effect on the 2-year disability wors-
ening.27 A combined measure of 1-year changes inMRI lesions
and relapses predicted 100% of the treatment effect on 2-year
disability worsening in IFN-β-treated patients.24 The combined
treatment effect on relapses and yearly percentage brain vol-
ume change over 2 years resulted to predict;73% of treatment
effect on disability worsening in fingolimod-treated patients.28
Table 1 Studies investigating the no evidence of disease activity (NEDA) constructs as outcome and percentage of
patients on treatment achieving respective goals
Follow-up, y NEDA-3 NEDA-4
2 23% Teriflunomide vs 14% placebo (TEMSO)e4 20% Fingolimod vs placebo 5% (FREEDOMS I & II)e17
25% Daclizumab vs 14% IM IFN-β-1a (DECIDE)e5 NA
26% Dimethyl fumarate vs 12% placebo (DEFINE and CONFIRM)e6 NA
32%–39% Alemtuzumab vs 13%–27% SC IFN-β-1a (CARE-MS I & II)e7,e8 NA
33% Fingolimod vs 10% placebo (FREEDOMS I & II)e9 NA
37% Natalizumab vs 7% placebo (AFFIRM)e3 NA
46% Cladribine vs 17% placebo (CLARITY)e10 NA
48% Ocrelizumab vs 25%–29% SC IFN-β-1a (OPERA I & II)e11
83% AHSCTe12,a NA
3 33% GA plus SC IFN-β-1a vs 21% SC IFN-β-1a vs 19% GA (Combi-RX)e13 NA
5 67% AHSCTe12,a NA
7 8% Independent of disease-modifying drugse14,b NA
34% Natalizumabe15,b NA
10 0% IM IFN-β-1ae16,b 9% BRACEe18,b
Abbreviations: AFFIRM = Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis; AHSCT = autologous hematopoietic stem cell trans-
plantation; BRACE = Betaferon, Rebif, Avonex, Copaxone, Extavia; CARE-MS = Comparison of Alemtuzumab and Rebif® Efficacy inMultiple Sclerosis; CLARITY
= A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS); CONFIRM = Efficacy and Safety Study of Oral
BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis; DECIDE = Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus
Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis; DEFINE = Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple
Sclerosis; FREEDOMS = Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis; GA = glatiramer acetate; IFN-β =
interferon-β; NA = not available; NEDA-3 = no relapse, no confirmed worsening of disability, no active MRI lesion; NEDA-4 = no relapse, no confirmed
worsening of disability, no active MRI lesion, no significant brain volume loss; OPERA = A Study of Ocrelizumab in ComparisonWith Interferon Beta-1a (Rebif)
in Participants With Relapsing Multiple Sclerosis; TEMSO = Teriflunomide Multiple Sclerosis Oral.
a Meta-analysis of observational studies.
b Observational, uncontrolled studies: see e-references e1–e18 (available at magnims.eu/?protected-download=16119).
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Monitoring treatment
response clinically
Relapses are the main feature of RRMS and it is well-
established that relapse rate in the first year of treatment
appears to be correlated with short-term disability.
The pivotal trial of intramuscular IFN-β-1a demonstrated that
patients with ≥2 relapses during the first 2 treatment years had
a higher risk of being in the worst EDSS quartile at 15 years
(odds ratio 4.44; p = 0.01).3 Interestingly, experiencing ≥2
relapses in patients treated with placebo was not associated
with this poor outcome. This latter observation raised the
hypothesis that those who present persistent inflammatory
activity early on IFN-β treatment represent a pathogenetically
distinct subset of patients whose fingerprint is an exaggerated
molecular response to IFN-β.29 Similarly, another long-term
study of patients included in the pivotal trial on subcutaneous
IFN-β-1b showed that changes in EDSS (p < 0.001) and
relapse rate (p = 0.025) during the study (0–2 years) were
associated with a higher risk of reaching an EDSS score of 6.0
or transitioning to SPMS after 16 years.3 Again, in a cohort of
patients who began IFN-β therapy between 1995 and 2001 in
Barcelona, the presence of relapses or EDSS worsening during
the first 2 treatment years was associated with an increased
risk of developing SPMS, attaining an EDSS score of 7.5, or
exhibiting an increase of ≥5 EDSS steps after 12 years.18
However, the presence of an isolated relapse without changes
in EDSS during the first 2 treatment years did not significantly
increase the risk of developing marked long-term disability,
supporting an earlier postmarketing study that pointed out
the low accuracy of clinical relapses in predicting accumula-
tion of disability over a median time period of 5 years.21
Overall, clinical activity measures at 1 or 2 years had moderate
to good specificity and low to moderate sensitivity to this
outcome.18,30 Other recent studies have also confirmed that
clinical activity, defined as EDSS change or relapses during the
first years of IFN-β treatment, had a very negative effect on
long-term prognosis.17,22
It is clear, therefore, that the presence of clinical and MRI
activity in the short term is predictive of negative prognosis
and vice versa. There are, however, some concerns when only
relapses are adopted to predict treatment response:
1. Relapse rate is influenced by both a regression to the
mean phenomenon (due to inclusion of active patients)
and a general shift in trials to milder MS populations (in
an era with increasingly effective drugs).
2. Relapses can be affected by recall bias from patients and
observer bias from clinicians.
3. Excluding pseudoexacerbations is not always possible.
4. Waiting for a relapse may expose patients to risk of
accumulating disability.




Conventional MRI (i.e., T2-weighted and contrast-enhanced
T1-weighted sequences) represents a powerful tool to monitor
disease activity in MS. Active lesions on MRI are 5–10 times
more frequent than clinical relapses, especially in patients with
RRMS. Therefore, the persistence of the inflammatory com-
ponent of the disease, such as gadolinium-enhancing lesions
or new/enlarged T2-hyperintense lesions, suggests a partial
or even absent biological effect of treatment. However, T1-
hypointense lesions (black holes), representing areas of
chronic axonal loss more strictly correlated with current
disability, were considered hardly ever and thereby there are
limited data on the treatment effect on this MRI marker.31
A post hoc analysis of the original trial on intramuscular IFN-
β-1a found poor disability outcome associated with the oc-
currence of ≥2 on-study relapses in both active and placebo
groups, whereas accumulation of >2 new/enlarged T2 lesions
was associated with poor disability outcome in the active group,
but not in the placebo group.32 This latter observation supports
the greater sensitivity of MRI measures over clinical features in
determining the responsiveness of IFN-β treatment.
Post hoc analyses of clinical trials on IFN-β-1a and -1b clearly
showed that the treatment effect on new T2 lesions in the first
treatment year accounted for a relevant proportion of treat-
ment effect on relapses (;70%–80%) and disability wors-
ening (;60%) over the subsequent year.24,26,27
Postmarketing MRI-based studies have suggested a clinically
relevant association between the occurrence of MRI activity
after 6–12months of treatment and poorer outcomes over the
medium-term period. This relationship survives even in ab-
sence of early clinical activity (i.e., in the first 6–12 months
of treatment) and irrespective of the adopted definition of
treatment response (e.g., occurrence of relapses or confirmed
EDSS worsening).4,30,33 However, one can argue that—in the
absence of a comparison group—the detection of MRI ac-
tivity may reflect a poor disease prognosis rather than a lack of
treatment response.
Two studies described a dose–effect relationship between
new MRI lesions and the risk of future relapses34 or accu-
mulation of disability.30 Active MRI lesions in functionally
eloquent areas, such as brainstem and spinal cord, were re-
lated with an increased risk of future EDSS worsening.34 Such
infratentorial (especially brainstem) or spinal cord damage is
closely associated with clinical disability, independently from
brain atrophy and other MRI metrics.35,36
There is controversy about what degree or threshold of MRI
activity should be accepted before defining a patient as
a treatment nonresponder. Published studies suggest different
cutoff of MRI lesions (in some cases even just 1 or 2 new
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lesions), and differently weighted the risk of treatment failure
if the new lesion was gadolinium-enhancing or not.5,30,33,34,37
These discrepancies across studies are mainly due to technical
issues in lesion detection and quantification (table 2):
1. Accurate detection and counting of new/enlarged T2
lesions is closely dependent on technical factors such as
scan repositioning, slice thickness, and quality of image
acquisition.38
2. Detection and counting of gadolinium-enhancing lesions
is easier and more reliable, but not sufficiently sensitive,
since an overt breakdown of the blood–brain barrier
(BBB) is typically short-lived (few weeks) and occurs
almost exclusively in newly acute lesions, while a low-
grade BBB disruption occurs also in chronic active
(nonenhancing) lesions.
3. Detection and counting of gadolinium-enhancing lesions
also depends on MRI acquisition protocol, contrast
administration strategy (e.g., delay between injection and
image acquisition, contrast dose), and physicochemical
features of gadolinium-based contrast agents (brain
deposition of gadolinium-based contrast agents in
patients who had repeated administrations39 should be
also taken into account in the future selection of contrast
agents for safety reasons).
4. Active lesion assessment is usually performed visually,
resulting in almost perfect reliability for gadolinium-
enhancing lesions, but moderate to substantial reliability
for new T2 lesions and low reliability for enlarging T2
lesions.40
5. Residual disease activity can still occur in the first few
months of treatment, due to a delay in the treatment
response; thus, the timing of the baseline MRI should
be based on the pharmacodynamics of the treatment
concerned, i.e., after a sufficient time frame allowing the
drug to start working, usually 3–6 months. For example,
the maximal effect on MRI activity was found to start
after 3 months for dimethyl fumarate and 7 months for
GA.41,42 However, the kinetics of the onset of action
and the time for reaching the full benefit are not known
precisely for any drug.
6. Spinal cord lesions are often neglected. Although many
spinal cord lesions are clinically symptomatic, new spinal
cord lesions may occur even in the absence of clinical
signs or symptoms, and without subclinical brain MRI
activity.43 Spinal cord lesions may be more strongly
correlated with future disability accrual even while on
treatment.34 However, image artefacts due to vascular
and CSF pulsation during spinal cord MRI acquisition
make spinal cord MRI difficult to standardize. As
a consequence, the use of spinal cord imaging for
assessing treatment response seems rather limited.38
Scoring treatment response
The first attempt of combining clinical and MRI activity
measures to predict treatment response was made by the
Canadian MS Working Group (CMSWG) that provided the
Treatment Optimization Recommendations (TOR) in
2004.44 The CMSWG presented an analogic model, derived
from expert consensus, based on different levels of concern
about the occurrence of disability worsening, relapses, and
MRI activity during treatment. These levels of concern were
classified as low, medium, and high. Although the TOR
framework did not provide quantitative rules, when applied to
Prevention of Relapses and disability by Interferon beta-1a
Subcutaneously in Multiple Sclerosis (PRISMS) data (using
relapse and disability worsening only), 89% of patients clas-
sified as having a medium or high level of concern after 1 year
of treatment went on to develop further breakthrough disease
over the next 2–4 years.45 More recently, the CMSWG pro-
posed an updated framework, suggesting that a change in
treatment might be considered if there is a high level of
concern in any one domain (relapses, progression, or MRI
activity), a medium level of concern in any 2 domains, or a low
level of concern in all 3 domains.46
Rı́o et al.37 analyzed 222 patients treated with one IFN-β
formulation for ≥1 year, combining clinical relapses, disability
worsening (as measured by a 1-point EDSS increase con-
firmed at 6 months), and active MRI (defined as >2 new T2-
hyperintense or gadolinium-enhancing lesions). Patients who
were positive for at least 2 of the 3 criteria analyzed after the
first year of treatment were found to have a higher probability
of having a new relapse or disability increase in the subsequent
2 years. These individuals would, therefore, be strong candi-
dates for a treatment switch (although this has not been tested
in a randomized trial). Of note, the isolated presence of
Table 2 Technical issues affecting MRI lesion detection and quantification
Gadolinium-enhancing lesions T2-hyperintense lesions
Physicochemical features of gadolinium-based contrast agents Scan repositioning
Contrast administration strategy (e.g., delay between injection
and image acquisition, contrast dose)
Artefacts due to vascular and CSF pulsation (especially for spinal cord imaging)
Slice thickness
Quality of image acquisition
Field strength
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relapses or MRI activity during year 1 did not predict the risk
of new clinical activity or disease progression in the ensuing 2
years. In addition, an increase in disability alone during the
first treatment year was a poor predictor of subsequent dis-
ability worsening.
After this publication, Sormani and coworkers47 simplified the
assessment proposed by Ŕıo et al.37 through a scoring system
(the so-called Modified Ŕıo Score) based on only new T2
lesions and relapses as components. The rationale for using
only these 2markers came from evidence that the effect of IFN-
β on the combination of MRI activity and relapses in the first
year accounts for almost 100% of treatment effect on disability
worsening at 2 years.24 Cutoff values for the number of relapses
and the number of new T2 lesions counted over the first
treatment year were established by statistical modeling of data
provided by the active arms of the PRISMS trial (training
set).47 The results of this analysis were validated using the real-
world dataset that was used for developing the original Rio
Score (validation set). The Modified Rı́o Score stratified
patients into 3 risk groups according to the probability of dis-
ability worsening: low (24%), medium (33%), and high risk
(65%), with excellent specificity (97%) and very low sensitivity
(24%) in discriminating treatment response. TheModified Rio
Score was further refined to encompass a new clinical visit and
a new brain MRI at 6 months (for identifying relapses or the
presence of ≥2 new T2 lesions) after the first treatment year, in
order to allow a better classification of patients in the medium
risk group, who were the most difficult to classify in terms of
future treatment response and planning.48
One criticism of theModified Rio Score is the somewhat higher
threshold of MRI activity (>4 new T2 lesions) required to
define substantial MRI activity that translates into a low sensi-
tivity to detect treatment response. The latter likely reflects the
disease activity as assessed on an old dataset such as the
PRISMS cohort (used as the training set), especially if com-
pared withmore recent trial cohorts and real-world populations.
Subsequently, a larger and more recent multicenter dataset
was collected within the MAGNIMS Study Group to explore
whether minimal MRI activity can be accepted or substantial
MRI activity (eventually in combination with clinical relap-
ses) should alert for a suboptimal treatment response.11 The
presence of relapses during the first IFN-β year was the main
predictor of the risk of treatment failure over the subsequent 3
years. Moreover, the presence of substantial MRI activity,
here defined by ≥3 new T2 lesions, increased the ability to
predict treatment failure (figure 2). The study concludes that
substantial MRI activity during the first year of treatment with
IFN-β, particularly if in combination with clinical relapses,
indicates significant risk of treatment failure and EDSS
worsening in the short term.
Table 3 summarizes the advantages and disadvantages asso-
ciated with the use of MRI activity alone and quantitative
scoring systems.
Assessing treatment response to drugs
other than IFN-β
One important weakness when evaluating tools for assessing
treatment response is that the vast majority of studies are
based upon patients on IFN-β treatment, with limited data
from cohorts of patients treated with other drugs.
In 2014, Ŕıo et al.49 evaluated if their previous scoring system
used to assess response to IFN-β could also be applied to GA.
Patients were classified as active (clinical and MRI activity),
inactive (none), and partially active (clinical or MRI activity)
after the first treatment year. Patients classified as active during
the first year were at an increased risk of continued clinical
activity over the next 2 years. Interestingly, while the prognosis of
active patients on GA was similar to that reported in patients
treated with IFN-β, the partially active group showed a different
clinical evolution. Patients with isolated clinical activity had
a significant risk of new activity in the next 2 years. By contrast,
patients with isolated MRI activity during the first year of
treatment did not show a significant risk of future disease activity.
These findings can be explained by the different mechanisms of
action of the 2 drugs. While IFN-β rapidly inhibits BBB leakage
and gadolinium enhancement within 2 weeks,50 GA shows
a slower rate of BBB stabilization and a less dramatic resolution
of gadolinium-enhancing activity.51 Consequently, MRI meas-
ures used to assess treatment response in patients receiving IFN-
β are not necessarily applicable to patients with GA.
Attempts to define treatment response to the newerMS drugs
fingolimod and teriflunomide have been made recently.
Boster et al.52 investigated whether MRI activity or relapses
during the first 12 months of treatment with fingolimod
(M0–M12) predicted disease activity over the following 36
months on treatment in the pooled extension populations of
the Efficacy and Safety of Fingolimod (FTY720) in Patients
With Relapsing-Remitting Multiple Sclerosis (FREEDOMS)
and FREEDOMS II trials. They found that either relapses or
MRI activity or their combination effectively predicted future
relapses and disability worsening.
Sormani et al.53 confirmed that ≥1 relapses during the first
year of fingolimod increased the risk of confirmed disability
worsening over 4 years on treatment in patients in the
FREEDOMS and FREEDOMS II trials. To investigate the
added value of MRI, patients who were relapse-free during
the first treatment year were analyzed separately. Persistent
lesion formation (defined as presence of new T2 lesions in
both the first and second 6 months of treatment) represented
a better predictor than the crude number of new T2 lesions in
identifying patients at higher risk of future disability. More-
over, the combination of 1-year persistent MRI lesion activity
and substantial brain atrophy (defined here as a percentage
brain volume loss >0.8%) was associated with a higher risk of
disability worsening compared with no persistent lesion for-
mation and percentage brain volume loss ≤0.8%.
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The risk of disability worsening with teriflunomide was in-
vestigated in the Teriflunomide Multiple Sclerosis Oral
(TEMSO) core study and extension population54 using the
score previously developed by the MAGNIMS Study Group,
based on the occurrence of relapses (0 to ≥2) and new/
enlarging T2 lesions (<3 or ≥3).11 After the first year of teri-
flunomide treatment, patients were classified into risk score
categories as follows: 0 = low, 1 = intermediate, either 2 or 3 =
high. The risk of confirmed disability worsening over the 7-year
follow-up period was significantly higher for patients in cate-
gories 2 or 3 than in those scoring 0 (hazard ratio [HR] 1.96, p
= 0.004). At 18-month follow-up, patients in the intermediate-
risk group (26% of the whole population) were reclassified as
responders (0 relapses or <2 newT2 lesions) or nonresponders
(≥1 relapses or ≥2 new T2 lesions). Patients reclassified as
nonresponders had a higher risk of disability worsening than
those reclassified as responders (HR 1.92, p < 0.001).
Suggestions for changing treatment when using injectable
therapies and, to a certain degree, oral licensed drugs, are
probably different from those of more effective drugs, such as
natalizumab and alemtuzumab. While treatment failure was
often associated with early disease activity on IFN-β or GA,8
carryover disease activity was described in a subgroup of
natalizumab-treated patients who experienced MRI activity in
the first treatment year without subsequent relapses or EDSS
worsening,55 especially in case of higher baseline MRI activ-
ity.56 On the other hand, any new lesions beyond 18 months
Figure 2 Treatment failure–free survival and disability worsening–free survival
Treatment failure–free survival (defined as switch to
a second-line treatment for lack of efficacy) (A) and dis-
ability worsening–free survival (defined as an at least 1-
point Expanded Disability Status Scale [EDSS] increase)
(B) over 3 years, according to the different combinations
of new T2 lesions and relapses during the first year of
therapy grouped in a 3-level score, in a cohort of 1,280
patients treated with interferon-β (modified from Sor-
mani et al.11).
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of natalizumab therapy should be considered as a suspected
adverse event of progressive multifocal leukoencephalop-
athy.38 Disease activity occurring after immune cell-depletive
agents, such as alemtuzumab or cladribine, can be contem-
plated as an indication to retreat the patient.57
Recommendations and
future directions
1. Future clinical trials should adopt NEDA as composite
endpoint to evaluate treatment efficacy, since it is more
sensitive than traditional clinical measures (relapse rates
and disability worsening) and requires fewer patients
especially for head-to-head study design.
2. Many other phenomena could be incorporated into the
NEDA endpoint, with the ultimate goal of suppressing all
aspects of disease activity and progression (figure 3).
3. In the real-world setting, NEDA currently seems to be an
unrealistic treatment goal over the long term, thereby
identifying a need to define aMEDA that can be tolerated
before treatment switching.
4. The residual disease activity carrying over during the first
few months of treatment should be always taken into
account when using MRI to monitor effects of treatment.
The residual disease activity could affect the assessment
of NEDA, which should therefore account for the time
frame allowing the drug to reach efficacy (usually 3–6
months).
5. Future investigation is warranted to better elucidate if
drugs with different mechanisms of action share (or not)
the same predictors of treatment response.
6. Although methods for precise quantitative analyses of
MRI lesion already exist and have been used in clinical
trials for many years, strong efforts are being made to
develop automated quantitative lesion segmentation by
dedicated software with the aim of increasing accuracy in
lesion detection while decreasing time of analyses.58–60
Application of automated MRI subtraction can improve
interpretation of serial imaging, but this approach cannot
be incorporated into daily clinical practice until validation
studies are performed and technical improvements are
achieved.
The MAGNIMS Study Group discussed how to define and
monitor response toMS treatments, and concluded that there
is no shared consensus on definition of treatment response.
While NEDA may represent a future endpoint in the exper-
imental setting, its attainability in the real world is contro-
versial. Clinical and MRI activity in isolation may be not
sufficient to determine treatment response, whereas the
combination of these measures using composite scores
appears preferable. Although this article is based on the most
recent literature data, periodic updates are needed in the light
of the near introduction of newer drugs active against MS and
technological innovations in MRI lesion detection and
counting.
Table 3 Pros and cons of clinical scoring systems vsMRI-based disease activity to predict treatment response inmultiple
sclerosis
Pros Cons
Clinical scoring systems High specificity Low sensitivity
Perfect surrogate: 100% of treatment effect on
short-term disability worsening explained (only in
IFN-β-treated patients)
Severity and recovery from relapses usually is not considered
Relapse count is affected by the following:
Era (lowering over recent years due to earlier diagnosis)
Disease duration (natural history of decrease over time)
Number of neurologic visits
Possibility of pseudoexacerbations
MRI-based disease activity High sensitivity Low specificity
Closely related to the undergoing pathologic process Cutoff for number of MRI lesions is not established
Need to rebaseline relative to the time to full treatment effect
(i.e., new T2 lesions may be due to residual disease activity in
the first few months of treatment)
New MRI lesions in spinal cord are usually not considered
MRI measures more closely related to prognosis (e.g., lesion
location) or pathology (e.g., black holes) are not considered
Abbreviation: IFN-β = interferon-β.
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